Utility of dose frequency adjustment in tocilizumab administration for rheumatoid arthritis

Shuntaro Saito, Yuko Kaneko, Keisuke Izumi, Tsutomu Takeuchi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective. To assess the utility of dose frequency adjustment of tocilizumab (TCZ) in rheumatoid arthritis (RA). Methods. Patients who received TCZ at 3-week (n = 24) or 5-week (n = 61) interval were evaluated. Results. Disease Activity Score at 28 joints based on erythrocyte sedimentation rate in the 3-week group significantly improved after 3 administrations at 3-week intervals (from 4.2 to 2.7, p = 0.001). Forty-five of the patients in the 5-week group (74%) successfully continued 5-week interval administration without disease exacerbation. Lower C-reactive protein level at TCZ initiation and shorter duration to remission achievement were key to successful dose frequency reduction. Conclusion. Adjusting the dose frequency of intravenous TCZ is a useful strategy.

Original languageEnglish
Pages (from-to)553-557
Number of pages5
JournalJournal of Rheumatology
Volume44
Issue number5
DOIs
Publication statusPublished - 2017 May 1

Keywords

  • Arthritis
  • Rheumatoid
  • Tocilizumab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology

Fingerprint Dive into the research topics of 'Utility of dose frequency adjustment in tocilizumab administration for rheumatoid arthritis'. Together they form a unique fingerprint.

  • Cite this